Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

"…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …"

Disturbances in drylands: Interactions among herbivory, drought, and termite activity in savanna plant communities حسب Harry Wells (11430190)

"…The impacts of these events may be modulated by biotic agents in unpredictable ways, yet few experiments cover sufficient spatiotemporal scales to measure the interactive effects of multiple extreme events. We used 15 years of a 28-year experiment spanning several significant droughts to investigate how rainfall, large herbivores, and soil-engineering termites affect understory vegetation in a semi-arid savanna. …"

Video 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.mp4 حسب Xin Fei (20466992)

"…After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …"

Image 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.jpeg حسب Xin Fei (20466992)

"…After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …"

Video 2_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.mp4 حسب Xin Fei (20466992)

"…After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …"

Table 4_Inoculation frequency and maize genotype influence plant growth-promoting effects of soil bacteria under low nitrogen conditions.xlsx حسب Lexie R. Foster (22235653)

"…This was carried out through non-repeated and repeated bacterial inoculations using different maize genotypes. We identified several growth-promoting bacterial isolates and observed a significant interaction between the bacterial isolates and the maize genotype, suggesting a strong interaction between the host genetics and the effects of bacterial isolates. …"

Dataset and R code for Humann-Guilleminot et al. - Dose-dependent effects of cadmium on food consumption, mass, and bioaccumulation in the moth <i>Spodoptera littoralis.</i> حسب Ségolène Humann-Guilleminot (20908844)

"…In addition, our results indicated that cadmium accumulation reached its maximum at pupal stage and decreased in adults, suggesting that efficient detoxification processes occur during metamorphosis, with significant amounts of cadmium that were excreted through the integument and exuviae at the pre-pupal stage. …"

Table 3_Global, regional, and national burden of acute hepatitis (1990–2021): a systematic analysis of the global burden of disease in 2021.xlsx حسب Zhixun Bai (14021787)

"…</p>Conclusion<p>While global AVH burden is decreasing, significant disparities persist, warranting tailored interventions to enhance resource equity in high-SDI regions and strengthen healthcare infrastructure in low-SDI areas.…"

Data Sheet 1_Antibacterial effects of coniferyl alcohol-derived dehydrogenation polymer on chlamydial infection in vitro.pdf حسب Anna Pfundner (22409281)

"…To investigate its effects on Chlamydia-infected cells, we employed flow cytometry-based assays, fluorescence microscopy, and quantitative PCR (qPCR). …"

Data Sheet 1_Role of RGS17 in cisplatin-induced cochlear inflammation and ototoxicity via caspase-3 activation.zip حسب Raheem F. H. Al Aameri (14951800)

"…<p>Cisplatin is a chemotherapy drug used to treat different solid tumors, including ovarian, bladder, lung, and head and neck cancers. One of its significant side effects is ototoxicity, especially when high doses are required. …"

Table 2_Global, regional, and national burden of acute hepatitis (1990–2021): a systematic analysis of the global burden of disease in 2021.xlsx حسب Zhixun Bai (14021787)

"…</p>Conclusion<p>While global AVH burden is decreasing, significant disparities persist, warranting tailored interventions to enhance resource equity in high-SDI regions and strengthen healthcare infrastructure in low-SDI areas.…"